Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney Cancer

The Food and Drug Administration has approved cabozantinib (Cabometyx®) as an initial treatment for patients with advanced renal cell carcinoma, the most common type of kidney cancer.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2otWOQu